Other transactionsDe Witte Jan
Filing context
Reporting owners and roles: De Witte Jan (director)
- De Witte JanTax/exercise-price payment59.981 shares · $14,042.15
Transaction details
director · Direct ownership · ResMed Common Stock · Code F/D
| Source | 12M Target | 12M Range | Analysts | Updated |
|---|---|---|---|---|
| StockAnalysis | $264.33USD | $210.00 – $320.00USD | 17 | — |
MarketBeat data unavailable
| Fiscal quarter | Period | Value | Change YoY | SEC filing |
|---|---|---|---|---|
| FY2027 Q1 | – | 1,414,814,000 USD | +5.9% | |
| FY2026 Q4 | – | 1,463,647,000 USD | +8.6% | |
| FY2026 Q3 | – | 1,431,406,000 USD | +10.8% | |
| FY2026 Q2 | – | 1,422,808,000 USD | +11.0% | |
| FY2026 Q1 | – | 1,335,582,000 USD | +9.1% | |
| FY2025 Q4 | – | 1,347,993,000 USD | +10.2% | |
| FY2025 Q3 | – | 1,291,736,000 USD | +7.9% | |
| FY2025 Q2 | – | 1,282,089,000 USD | +10.3% |
| Fiscal quarter | Period | Value | Change YoY | SEC filing |
|---|---|---|---|---|
| FY2027 Q1 | – | 418,413,000 USD | +20.0% | |
| FY2026 Q4 | – | 383,432,000 USD | +1.0% | |
| FY2026 Q3 | – | 398,732,000 USD | +9.2% | |
| FY2026 Q2 | – | 392,593,000 USD | +13.9% | |
| FY2026 Q1 | – | 348,536,000 USD | +11.9% | |
| FY2025 Q4 | – | 379,705,000 USD | +29.9% | |
| FY2025 Q3 | – | 365,041,000 USD | +21.5% | |
| FY2025 Q2 | – | 344,622,000 USD | +65.0% |
| Fiscal quarter | Period | Value | Change YoY | SEC filing |
|---|---|---|---|---|
| FY2027 Q1 | – | 422,422,000 USD | -7.6% | |
| FY2026 Q4 | – | 454,631,000 USD | -15.6% | |
| FY2026 Q3 | – | 554,132,000 USD | -4.2% | |
| FY2026 Q2 | – | 339,745,000 USD | +10.1% | |
| FY2026 Q1 | – | 457,321,000 USD | +40.5% | |
| FY2025 Q4 | – | 538,766,000 USD | +22.4% | |
| FY2025 Q3 | – | 578,661,000 USD | +43.9% | |
| FY2025 Q2 | – | 308,623,000 USD | +13.1% |
5 sales, 14 other transactions reported.
Limited coverage · Checked Nov 14, 2026
Amendments may add or replace reported transactions; rows are not deduplicated economic totals.
Amendments or incomplete collection can affect the context. Linked observations remain available below.
Reporting owners and roles: De Witte Jan (director)
director · Direct ownership · ResMed Common Stock · Code F/D
Reporting owners and roles: FARRELL PETER C (director)
director · Direct ownership · ResMed Common Stock · Code F/D
Reporting owners and roles: Bloomer Aaron (officer (Chief Financial Officer))
officer (Chief Financial Officer) · Direct ownership · ResMed Common Stock · Code F/D
Reporting owners and roles: Farrell Michael J. (director, officer (Chairman and CEO))
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code F/D
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code F/D
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code F/D
Reporting owners and roles: Farrell Michael J. (director, officer (Chairman and CEO))
10b5-1 declared for this filing
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code M/A
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code M/A
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code S/D · 1.03% of before-trade holdings
Reporting owners and roles: Rider Michael J (officer (Global General Counsel))
10b5-1 declared for this filing
officer (Global General Counsel) · Direct ownership · ResMed Common Stock · Code S/D · 3.15% of before-trade holdings
Reporting owners and roles: Farrell Michael J. (director, officer (Chairman and CEO))
10b5-1 declared for this filing
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code M/A
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code S/D · 1.03% of before-trade holdings
Reporting owners and roles: Bloomer Aaron (officer (Chief Financial Officer))
officer (Chief Financial Officer) · Direct ownership · ResMed Common Stock · Code A/A
Reporting owners and roles: Farrell Michael J. (director, officer (Chairman and CEO))
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code A/A
Reporting owners and roles: Rider Michael J (officer (Global General Counsel))
officer (Global General Counsel) · Direct ownership · ResMed Common Stock · Code A/A
Reporting owners and roles: Leong Justin (officer (Chief Product Officer))
officer (Chief Product Officer) · Direct ownership · ResMed Common Stock · Code A/A
Reporting owners and roles: Farrell Michael J. (director, officer (Chairman and CEO))
Transaction details unavailable.
Reporting owners and roles: Farrell Michael J. (director, officer (Chairman and CEO))
10b5-1 declared for this filing
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code M/A
director, officer (Chairman and CEO) · Direct ownership · ResMed Common Stock · Code S/D · 1.06% of before-trade holdings
Reporting owners and roles: FARRELL PETER C (director)
10b5-1 declared for this filing
director · Direct ownership · ResMed Common Stock · Code S/D · 1.84% of before-trade holdings
Options, grants, withholding, and gifts are context, not voluntary market purchases or sales.
Reported sales can reflect planned or tax-related transactions and do not by themselves indicate a view on the stock.
Purchase and sale labels describe reported transaction codes; they do not indicate whether the transaction is favorable.